Photo: Pamela Tulizo/Getty Images

The Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' Inmazeb as the first treatment for the Ebola virus.

Why it matters: The approval comes after the World Health Organization announced in June that the world’s second-largest Ebola outbreak had been eradicated in the Democratic Republic of the Congo. There were over 3,400 cases and over 2,200 deaths, according to data from WHO.

Details: Inmazeb, a mixture of three antibodies, was tested on 382 adults and children with confirmed Zaire ebolavirus infection in a clinical trial conducted in the Democratic Republic of the Congo during an Ebola outbreak between 2018 and 2019, the FDA said.

What they're saying: “Today’s action demonstrates the FDA’s ongoing commitment to responding to public health threats — both domestically and abroad — on the basis of science and data,” FDA commissioner Stephen Hahn said.

Department of Health and Human Services Secretary Alex Azar called the approval “a momentous global health achievement that would have never occurred without American leadership.”

  • "The United States was proud to provide direct support for this treatment, through an expanded access protocol and a clinical trial conducted in a highly dangerous and insecure region of the DRC," Azar said.
  • "The Trump Administration made ending the 2018 Ebola outbreak one of its top global health priorities for the last two years, and these efforts have now left the U.S. and our African partners better prepared for the fight against the new outbreak in western DRC and for future health threats.”

Flashback: Ervebo became the first FDA-approved vaccine for the prevention of the Ebola virus in December 2019, supported by a study in Guinea conducted during a 2014-2016 outbreak.

Go deeper

Sep 24, 2020 - Health

Cuomo: New York will conduct its own review of coronavirus vaccine

New York Gov. Andrew Cuomo. Photo: Michael M. Santiago/Getty Images

New York Gov. Andrew Cuomo (D) said Thursday that the state will move forward with its own review process of coronavirus vaccines even if the Food and Drug Administration approves one or more for distribution and public use.

Why it matters: The motion could sow further public doubt that the federal government could release a vaccine based on political motives rather than safety and efficacy.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: McConnell urges White House not to strike stimulus deal before election — Republican senators defend Fauci as Trump escalates attacks.
  2. Health: The next wave is gaining steam.
  3. Education: Schools haven't become hotspots — University of Michigan students ordered to shelter-in-place.
Updated 2 hours ago - Politics & Policy

Biden has huge cash advantage over Trump as Election Day nears

Democratic presidential nominee Joe Biden in Wilmington, Delaware, on Monday. Photo: Drew Angerer/Getty Images

Democratic presidential nominee Joe Biden had $177.3 million in the bank at the end of September, per the latest Federal Election Commission filings.

Why it matters: President Trump's re-election campaign reported having $63.1 million in the bank at the end of last month, as campaigning enters the final stretch ahead of Election Day on Nov. 3.